December 6, 2022

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found no significant difference in cancer risk in patients with rheumatic disease and a history of malignancy taking biologic or targeted synthetic DMARDs compared to those treated with TNF inhibitors.


Leave a Reply

Your email address will not be published. Required fields are marked *